Cardiac Insight

Executive Summary

Cardiac Insight is a private diagnostics company specializing in cardiac monitoring solutions, including the FDA-cleared Solo ECG interpretative system (2017) and the Cardea 20/20® ECG system. Based in Kirkland, WA, and founded in 2010, the company focuses on comprehensive cardiac evaluation, particularly for athletes. Their products enable remote, real-time ECG monitoring and analysis, addressing the growing demand for digital health solutions in cardiovascular care. Despite limited public funding and valuation data, Cardiac Insight occupies a niche in the expanding remote cardiac monitoring market, which is projected to grow significantly due to aging populations and increased focus on preventive care. The company's differentiation lies in its athlete-specific applications and integrated diagnostic platforms, though it faces competition from larger players like AliveCor and iRhythm. With no recent news on partnerships or funding, the company's near-term trajectory depends on product adoption and regulatory expansions.

Upcoming Catalysts (preview)

• Q3 2026FDA clearance for next-generation wearable ECG device50% success
• Q4 2026Strategic partnership with a major sports league or telemedicine provider40% success
• H2 2026Publication of pivotal clinical data on Cardea 20/20® system60% success